{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T08:37:20Z","timestamp":1792831040106,"version":"4.5.0"},"reference-count":80,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100013061","name":"Jilin Scientific and Technological Development Program","doi-asserted-by":"publisher","award":["20260204057YY"],"award-info":[{"award-number":["20260204057YY"]}],"id":[{"id":"10.13039\/501100013061","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.bioorg.2026.110633","type":"journal-article","created":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T23:12:43Z","timestamp":1791501163000},"page":"110633","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Advances in KRASG12D-targeted therapy: from small-molecule inhibitors to PROTACs and molecular glues"],"prefix":"10.1016","volume":"183","author":[{"given":"Sichang","family":"Hao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianjiao","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinrong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongqiang","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengxue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huimin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/j.bioorg.2026.110633_bb0005","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1158\/0008-5472.CAN-19-3682","article-title":"The frequency of Ras mutations in Cancer","volume":"80","author":"Prior","year":"2020","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.bioorg.2026.110633_bb0010","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/nrc1097","article-title":"RAS oncogenes: the first 30 years","volume":"3","author":"Malumbres","year":"2003","journal-title":"Nat. Rev. Cancer"},{"issue":"11","key":"10.1016\/j.bioorg.2026.110633_bb0015","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/nrc3106","article-title":"RAS oncogenes: weaving a tumorigenic web","volume":"11","author":"Pylayeva-Gupta","year":"2011","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.bioorg.2026.110633_bb0020","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s12943-021-01422-7","article-title":"Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges","volume":"20","author":"Tang","year":"2021","journal-title":"Mol. Cancer"},{"issue":"10","key":"10.1016\/j.bioorg.2026.110633_bb0025","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1038\/s41591-022-02007-7","article-title":"Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor","volume":"28","author":"Hallin","year":"2022","journal-title":"Nat. Med."},{"issue":"7","key":"10.1016\/j.bioorg.2026.110633_bb0030","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.ccell.2024.06.001","article-title":"Anti-tumor efficacy of HRS-4642 and its potential combination with proteasome inhibition in KRAS G12D-mutant cancer","volume":"42","author":"Zhou","year":"2024","journal-title":"Cancer Cell"},{"issue":"12_Supplement","key":"10.1016\/j.bioorg.2026.110633_bb0035","doi-asserted-by":"crossref","first-page":"B083","DOI":"10.1158\/1535-7163.TARG-23-B083","article-title":"Abstract B083: secondary KRAS mutations lead to acquired resistance to KRASG12D inhibitor in colorectal cancer","volume":"22","author":"Lieb","year":"2023","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bioorg.2026.110633_bb0040","article-title":"Potent effects of dioscin against obesity in mice","volume":"5","author":"Liu","year":"2015","journal-title":"Sci. Rep."},{"issue":"6_Supplement","key":"10.1016\/j.bioorg.2026.110633_bb0045","doi-asserted-by":"crossref","first-page":"6050","DOI":"10.1158\/1538-7445.AM2024-6050","article-title":"Abstract 6050: targeting KRAS G12D mutant tumors with the PROTAC degrader RP03707","volume":"84","author":"Ji","year":"2024","journal-title":"Cancer Res."},{"issue":"6659","key":"10.1016\/j.bioorg.2026.110633_bb0050","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1126\/science.adj1001","article-title":"Targeting cancer with molecular glues","volume":"381","author":"Liu","year":"2023","journal-title":"Science"},{"issue":"7407","key":"10.1016\/j.bioorg.2026.110633_bb0055","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nature11252","article-title":"Comprehensive molecular characterization of human colon and rectal cancer","volume":"487","author":"The Cancer Genome Atlas Network","year":"2012","journal-title":"Nature"},{"issue":"15","key":"10.1016\/j.bioorg.2026.110633_bb0060","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.1158\/1078-0432.CCR-13-1762","article-title":"A RAS renaissance: emerging targeted therapies for KRAS-mutated non\u2013small cell lung cancer","volume":"20","author":"Vasan","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.bioorg.2026.110633_bb0065","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/s41419-022-05259-w","article-title":"Interplays of glucose metabolism and KRAS mutation in pancreatic ductal adenocarcinoma","volume":"13","author":"Liu","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bioorg.2026.110633_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.116058","article-title":"Unveiling the role of KRAS in tumor immune microenvironment","volume":"171","author":"Xu","year":"2024","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110633_bb0075","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-19288-6","article-title":"Immune modulatory effects of oncogenic KRAS in cancer","volume":"11","author":"Hamarsheh","year":"2020","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.bioorg.2026.110633_bb0080","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1007\/s13577-021-00576-2","article-title":"Regulation of KRAS protein expression by miR-544a and KRAS-LCS6 polymorphism in wild-type KRAS sporadic colon adenocarcinoma","volume":"34","author":"Marinovi\u0107","year":"2021","journal-title":"Hum. Cell"},{"key":"10.1016\/j.bioorg.2026.110633_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2024.117627","article-title":"Research progress on small molecule inhibitors targeting KRAS G12C with acrylamide structure and the strategies for solving KRAS inhibitor resistance","volume":"100","author":"Jiang","year":"2024","journal-title":"Bioorg. Med. Chem."},{"issue":"16","key":"10.1016\/j.bioorg.2026.110633_bb0090","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15164141","article-title":"Proteomic mapping of the interactome of KRAS mutants identifies new features of RAS signalling networks and the mechanism of action of Sotorasib","volume":"15","author":"Nolan","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.bioorg.2026.110633_bb0095","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2023.1276333","article-title":"Hyperactive KRAS\/MAPK signaling disrupts normal lymphatic vessel architecture and function","volume":"11","author":"Fernandes","year":"2023","journal-title":"Front. Cell Dev. Biol."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110633_bb0100","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/bjc.2017.399","article-title":"Targeting the Raf kinases in human cancer: the Raf dimer dilemma","volume":"118","author":"Durrant","year":"2018","journal-title":"Br. J. Cancer"},{"issue":"7287","key":"10.1016\/j.bioorg.2026.110633_bb0105","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/nature08902","article-title":"RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF","volume":"464","author":"Poulikakos","year":"2010","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.bioorg.2026.110633_bb0110","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.3390\/curroncol31040150","article-title":"KRAS: biology, inhibition, and mechanisms of inhibitor resistance","volume":"31","author":"Ash","year":"2024","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.bioorg.2026.110633_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2023.155093","article-title":"Salvianolic acid F suppresses KRAS-dependent lung cancer cell growth through the PI3K\/AKT signaling pathway","volume":"121","author":"Hou","year":"2023","journal-title":"Phytomedicine"},{"issue":"12","key":"10.1016\/j.bioorg.2026.110633_bb0120","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1093\/oncolo\/oyac179","article-title":"KRAS mutation variants and co-occurring PI3K pathway alterations impact survival for patients with pancreatic ductal adenocarcinomas","volume":"27","author":"Diehl","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.bioorg.2026.110633_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216783","article-title":"Myotubularin-related-protein-7 inhibits mutant (G12V) K-RAS by direct interaction","volume":"588","author":"Weidner","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bioorg.2026.110633_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.107092","article-title":"Multiple medicinal chemistry strategies of targeting KRAS: state-of-the art and future directions","volume":"144","author":"Shang","year":"2024","journal-title":"Bioorg. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110633_bb0135","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/s41392-021-00780-4","article-title":"KRAS mutation: from undruggable to druggable in cancer","volume":"6","author":"Huang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"issue":"7","key":"10.1016\/j.bioorg.2026.110633_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e28495","article-title":"Design, synthesis, and evaluation of purine and pyrimidine-based KRAS G12D inhibitors: towards potential anticancer therapy","volume":"10","author":"Park","year":"2024","journal-title":"Heliyon"},{"issue":"17_Supplement_2","key":"10.1016\/j.bioorg.2026.110633_bb0145","doi-asserted-by":"crossref","first-page":"C012","DOI":"10.1158\/1538-7445.PANCREATIC24-C012","article-title":"Abstract C012: overcoming cell subtype-specific adaptive resistance to KRAS G12D inhibition in KRAS G12D-mutant pancreatic cancer","volume":"84","author":"Lin","year":"2024","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110633_bb0150","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s12672-022-00550-w","article-title":"Cytotoxicity of combinations of the pan-KRAS SOS1 inhibitor BAY-293 against pancreatic cancer cell lines","volume":"13","author":"Plangger","year":"2022","journal-title":"Discov. Oncol."},{"issue":"7968","key":"10.1016\/j.bioorg.2026.110633_bb0155","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/s41586-023-06123-3","article-title":"Pan-KRAS inhibitor disables oncogenic signalling and tumour growth","volume":"619","author":"Kim","year":"2023","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.bioorg.2026.110633_bb0160","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.trecan.2023.07.010","article-title":"Next batter up! Targeting cancers with KRAS-G12D mutations","volume":"9","author":"Zeissig","year":"2023","journal-title":"Trends Cancer"},{"issue":"13","key":"10.1016\/j.bioorg.2026.110633_bb0165","doi-asserted-by":"crossref","first-page":"6679","DOI":"10.1021\/acs.jmedchem.9b02052","article-title":"Identification of the clinical development candidate MRTX849, a covalent KRAS(G12C) inhibitor for the treatment of Cancer","volume":"63","author":"Fell","year":"2020","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110633_bb0170","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1021\/acs.jmedchem.9b01180","article-title":"Discovery of a covalent inhibitor of KRAS(G12C) (AMG 510) for the treatment of solid tumors","volume":"63","author":"Lanman","year":"2020","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110633_bb0175","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1021\/acs.jmedchem.1c01688","article-title":"Identification of MRTX1133, a noncovalent, potent, and selective KRASG12D inhibitor","volume":"65","author":"Wang","year":"2022","journal-title":"J. Med. Chem."},{"issue":"8","key":"10.1016\/j.bioorg.2026.110633_bb0180","doi-asserted-by":"crossref","first-page":"6044","DOI":"10.1021\/acs.jmedchem.3c02403","article-title":"Targeting KRAS diversity: covalent modulation of G12X and beyond in Cancer therapy","volume":"67","author":"Kirschner","year":"2024","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110633_bb0185","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1021\/acs.jmedchem.2c00099","article-title":"Drugging the next undruggable KRAS allele-Gly12Asp","volume":"65","author":"Zheng","year":"2022","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110633_bb0190","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1002\/prot.21253","article-title":"Strong and weak hydrogen bonds in the protein-ligand interface","volume":"67","author":"Panigrahi","year":"2007","journal-title":"Proteins"},{"issue":"34","key":"10.1016\/j.bioorg.2026.110633_bb0195","doi-asserted-by":"crossref","first-page":"3476","DOI":"10.2174\/138161207782794284","article-title":"The role and significance of unconventional hydrogen bonds in small molecule recognition by biological receptors of pharmaceutical relevance","volume":"13","author":"T\u00f3th","year":"2007","journal-title":"Curr. Pharm. Des."},{"issue":"1\u20133","key":"10.1016\/j.bioorg.2026.110633_bb0200","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"46","author":"Lipinski","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"6","key":"10.1016\/j.bioorg.2026.110633_bb0205","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1021\/cn100007x","article-title":"Defining desirable central nervous system drug space through the alignment of molecular properties, in vitro ADME, and safety attributes","volume":"1","author":"Wager","year":"2010","journal-title":"ACS Chem. Neurosci."},{"issue":"7","key":"10.1016\/j.bioorg.2026.110633_bb0210","doi-asserted-by":"crossref","first-page":"7211","DOI":"10.1021\/acsomega.3c00329","article-title":"Discovery of prodrug of MRTX1133 as an Oral therapy for cancers with KRASG12D mutation","volume":"8","author":"Ji","year":"2023","journal-title":"ACS Omega"},{"issue":"7","key":"10.1016\/j.bioorg.2026.110633_bb0215","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.ccell.2024.06.005","article-title":"HRS-4642: the next piece of the puzzle to keep KRAS in check","volume":"42","author":"Flores-G\u00f3mez","year":"2024","journal-title":"Cancer Cell"},{"issue":"37","key":"10.1016\/j.bioorg.2026.110633_bb0220","doi-asserted-by":"crossref","first-page":"20403","DOI":"10.1021\/jacs.3c05899","article-title":"Simultaneous covalent modification of K-Ras(G12D) and K-Ras(G12C) with Tunable oxirane electrophiles","volume":"145","author":"Yu","year":"2023","journal-title":"J. Am. Chem. Soc."},{"issue":"9","key":"10.1016\/j.bioorg.2026.110633_bb0225","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1038\/s41589-024-01565-w","article-title":"Strain-release alkylation of Asp12 enables mutant selective targeting of K-Ras-G12D","volume":"20","author":"Zheng","year":"2024","journal-title":"Nat. Chem. Biol."},{"issue":"25","key":"10.1016\/j.bioorg.2026.110633_bb0230","doi-asserted-by":"crossref","first-page":"3178","DOI":"10.1021\/acs.biochem.7b00271","article-title":"Expanding the scope of electrophiles capable of targeting K-Ras oncogenes","volume":"56","author":"McGregor","year":"2017","journal-title":"Biochemistry"},{"issue":"22","key":"10.1016\/j.bioorg.2026.110633_bb0235","doi-asserted-by":"crossref","first-page":"15524","DOI":"10.1021\/acs.jmedchem.3c01724","article-title":"Design, synthesis, and pharmacological evaluation of multisubstituted pyrido[4,3-d]pyrimidine analogues bearing deuterated methylene linkers as potent KRASG12D inhibitors","volume":"66","author":"Xiao","year":"2023","journal-title":"J. Med. Chem."},{"issue":"10","key":"10.1016\/j.bioorg.2026.110633_bb0240","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1016\/j.ccell.2025.07.006","article-title":"A pan-KRAS inhibitor and its derived degrader elicit multifaceted anti-tumor efficacy in KRAS-driven cancers","volume":"43","author":"Feng","year":"2025","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bioorg.2026.110633_bb0245","doi-asserted-by":"crossref","unstructured":"B.A. Lanman, R.P. Wurz, R. Verma, T. Osgood, K. Gaida, D. Mohn, Y.-C. Chen, G. Diaz, A.Y. Saiki, P.E. Hughes, C. Mohr, A. Vaish, Y. Tudor, U.P. Dahal, P. Agarwal, C. Mollica, Abstract ND01: AMG 410: an H\/NRAS-sparing pan-KRAS inhibitor with dual GTP(on)\/GDP(off)-state activity for the treatment of diverse KRAS-mutant tumors, Cancer Res. 85 (8_Supplement_2) (2025) ND01, Doi: https:\/\/doi.org\/10.1158\/1538-7445.AM2025-ND01.","DOI":"10.1158\/1538-7445.AM2025-ND01"},{"issue":"12","key":"10.1016\/j.bioorg.2026.110633_bb0250","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1021\/acsmedchemlett.8b00382","article-title":"Discovery of Tetrahydropyridopyrimidines as irreversible covalent inhibitors of KRAS-G12C with in vivo activity","volume":"9","author":"Fell","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110633_bb0255","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41421-021-00368-w","article-title":"KRAS(G12D) can be targeted by potent inhibitors via formation of salt bridge","volume":"8","author":"Mao","year":"2022","journal-title":"Cell Discov."},{"issue":"10","key":"10.1016\/j.bioorg.2026.110633_bb0260","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1021\/acsmedchemlett.3c00245","article-title":"Structure-based design and synthesis of potent and selective KRAS G12D inhibitors","volume":"14","author":"Cheng","year":"2023","journal-title":"ACS Med. Chem. Lett."},{"issue":"8_Supplement_2","key":"10.1016\/j.bioorg.2026.110633_bb0265","doi-asserted-by":"crossref","first-page":"ND11","DOI":"10.1158\/1538-7445.AM2025-ND11","article-title":"Abstract ND11: AZD0022: a potent, oral KRASG12D-selective inhibitor that drives robust pathway inhibition and anti-tumour activity in KRASG12D models","volume":"85","author":"Martins","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110633_bb0270","doi-asserted-by":"crossref","unstructured":"K. Beaumont, S. Guzzetti, P. Morentin-Gutierrez, R.D. Jones, K. Grime, C. Martins, A. Koers, A. Peter, S.T. Barry, S. Critchlow, M. Moschetta, M. Niedbala, Abstract 841: the preclinical pharmacokinetics and pharmacodynamics of AZD0022: a potent, oral KRASG12D-selective agent exhibiting oral bioavailability and KRAS pathway suppression in the GP2D xenograft model, Cancer Res. 85 (8_Supplement_1) (2025) 841, Doi: https:\/\/doi.org\/10.1158\/1538-7445.AM2025-841.","DOI":"10.1158\/1538-7445.AM2025-841"},{"issue":"5","key":"10.1016\/j.bioorg.2026.110633_bb0275","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/s41587-021-01126-9","article-title":"Conformation-locking antibodies for the discovery and characterization of KRAS inhibitors","volume":"40","author":"Davies","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bioorg.2026.110633_bb0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.118004","article-title":"The design and synthesis of selective and potent selenium-containing KRASG12D inhibitors","volume":"298","author":"Zhou","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110633_bb0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114243","article-title":"Discovery of Thieno[2,3-d]pyrimidine-based KRAS G12D inhibitors as potential anticancer agents via combinatorial virtual screening","volume":"233","author":"Li","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110633_bb0290","article-title":"Developing small molecules that inhibit K-Ras\/GTP binding based on new affinity measurements","author":"Carta","year":"2020","journal-title":"bioRxiv"},{"issue":"5","key":"10.1016\/j.bioorg.2026.110633_bb0295","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.cell.2017.02.006","article-title":"Multivalent small-molecule Pan-RAS inhibitors","volume":"168","author":"Welsch","year":"2017","journal-title":"Cell"},{"issue":"32","key":"10.1016\/j.bioorg.2026.110633_bb0300","doi-asserted-by":"crossref","first-page":"15823","DOI":"10.1073\/pnas.1904529116","article-title":"Drugging an undruggable pocket on KRAS","volume":"116","author":"Kessler","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"2","key":"10.1016\/j.bioorg.2026.110633_bb0305","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1021\/acs.jmedchem.4c02662","article-title":"Discovery of INCB159020, an orally bioavailable KRAS G12D inhibitor","volume":"68","author":"Ye","year":"2025","journal-title":"J. Med. Chem."},{"issue":"30","key":"10.1016\/j.bioorg.2026.110633_bb0310","doi-asserted-by":"crossref","first-page":"16610","DOI":"10.1021\/jacs.3c03886","article-title":"Development of orally bioavailable peptides targeting an intracellular protein: from a hit to a clinical KRAS inhibitor","volume":"145","author":"Tanada","year":"2023","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.bioorg.2026.110633_bb0315","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/978-1-4939-3673-1_5","article-title":"AlphaScreen-based assays: ultra-high-throughput screening for small-molecule inhibitors of challenging enzymes and protein-protein interactions","volume":"1439","author":"Yasgar","year":"2016","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.bioorg.2026.110633_bb0320","article-title":"Discovery of novel XPO1 PROTAC degraders for the treatment of acute myeloid leukemia","volume":"283","author":"Chen","year":"2025","journal-title":"Eur. J. Med. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110633_bb0325","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1021\/acs.jmedchem.3c01622","article-title":"Design, synthesis, and biological evaluation of potent and selective PROTAC degraders of oncogenic KRASG12D","volume":"67","author":"Zhou","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110633_bb0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107319","article-title":"Discovery of novel co-degradation CK1\u03b1 and CDK7\/9 PROTACs with p53 activation for treating acute myeloid leukemia","volume":"147","author":"Wang","year":"2024","journal-title":"Bioorg. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110633_bb0335","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s42004-025-01662-4","article-title":"Discovery of KRAS(G12D) selective degrader ASP3082","volume":"8","author":"Yoshinari","year":"2025","journal-title":"Commun. Chem."},{"issue":"6715","key":"10.1016\/j.bioorg.2026.110633_bb0340","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1126\/science.adm8684","article-title":"Targeting cancer with small-molecule pan-KRAS degraders","volume":"385","author":"Popow","year":"2024","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.bioorg.2026.110633_bb0345","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/s41416-021-01629-x","article-title":"Characterisation of a novel KRAS G12C inhibitor ASP2453 that shows potent anti-tumour activity in KRAS G12C-mutated preclinical models","volume":"126","author":"Nakayama","year":"2022","journal-title":"Br. J. Cancer"},{"issue":"14","key":"10.1016\/j.bioorg.2026.110633_bb0350","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1056\/NEJMoa2600752","article-title":"Setidegrasib in advanced non-small-cell lung cancer and pancreatic cancer","volume":"394","author":"Park","year":"2026","journal-title":"N. Engl. J. Med."},{"issue":"2_suppl","key":"10.1016\/j.bioorg.2026.110633_bb0355","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1200\/JCO.2026.44.2_suppl.775","article-title":"Phase 1 evaluation of ASP3082, a first-in-class selective protein degrader, in patients (pts) with KRAS G12D-mutant pancreatic ductal adenocarcinoma (PDAC): pharmacokinetics (PK) and biomarker insights","volume":"44","author":"Park","year":"2026","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bioorg.2026.110633_bb0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117928","article-title":"KRASG12D selective VHL-PROTAC with sparing KRASWT and other KRAS mutants","volume":"297","author":"Jeon","year":"2025","journal-title":"Eur. J. Med. Chem."},{"issue":"45","key":"10.1016\/j.bioorg.2026.110633_bb0365","doi-asserted-by":"crossref","first-page":"41367","DOI":"10.1021\/jacs.5c10354","article-title":"Identification of a highly cooperative PROTAC degrader targeting GTP-loaded KRAS(on) alleles","volume":"147","author":"Vetma","year":"2025","journal-title":"J. Am. Chem. Soc."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110633_bb0370","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1080\/14756366.2022.2087219","article-title":"Design, synthesis, and biological evaluation of a novel series of 2-(2,6-dioxopiperidin-3-yl)isoquinoline-1,3(2H,4H)-dione derivatives as cereblon modulators","volume":"37","author":"Liu","year":"2022","journal-title":"J. Enzyme Inhib. Med. Chem."},{"issue":"7_Supplement","key":"10.1016\/j.bioorg.2026.110633_bb0375","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2024-ND03","article-title":"Abstract ND03: discovery of RMC-9805, an oral, covalent tri-complex KRASG12D(ON) inhibitor","volume":"84","author":"Knox","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2026.110633_bb0380","doi-asserted-by":"crossref","unstructured":"M.J. Menard, C. Chow, K. Chen, C. Blaj, N.T. Shifrin, H. Courtney, N.M. Nasholm, A. Pham, A. Kumamoto, S. Ganesh, J.W. Evans, L. Lawrence, B. Vonmelchert, A.C. Kwok-Parkhill, J. Jiang, J.E. Knox, J. Smith, E. Quintana, Abstract 3475: RMC-9805, a first-in-class, mutant-selective, covalent and orally bioavailable KRASG12D(ON) inhibitor, promotes cancer-associated neoantigen recognition and synergizes with immunotherapy in preclinical models, Cancer Res. 83 (7_Supplement) (2023) 3475, Doi: https:\/\/doi.org\/10.1158\/1538-7445.AM2023-3475.","DOI":"10.1158\/1538-7445.AM2023-3475"},{"issue":"2","key":"10.1016\/j.bioorg.2026.110633_bb0385","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.apsb.2025.07.031","article-title":"Targeting oncogenic K-RAS mutants with small-molecule degrader XMU-MP-9 through NEDD4-1","volume":"16","author":"Zeng","year":"2026","journal-title":"Acta Pharm. Sin. B"},{"issue":"16","key":"10.1016\/j.bioorg.2026.110633_bb0390","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202100250","article-title":"Focal adhesion kinase (FAK) inhibition synergizes with KRAS G12C inhibitors in treating Cancer through the regulation of the FAK-YAP Signaling","volume":"8","author":"Zhang","year":"2021","journal-title":"Adv. Sci."},{"key":"10.1016\/j.bioorg.2026.110633_bb0395","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1004669","article-title":"Non-genetic adaptive resistance to KRASG12C inhibition: EMT is not the only culprit","volume":"12","author":"Ning","year":"2022","journal-title":"Front. Oncol."},{"issue":"9","key":"10.1016\/j.bioorg.2026.110633_bb0400","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1002\/cac2.12327","article-title":"KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1\/PD-L1 immunotherapy in non-small cell lung cancer","volume":"42","author":"Liu","year":"2022","journal-title":"Cancer Commun. (Lond.)"}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826011697?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826011697?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T08:01:21Z","timestamp":1792828881000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826011697"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":80,"alternative-id":["S0045206826011697"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110633","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in KRASG12D-targeted therapy: from small-molecule inhibitors to PROTACs and molecular glues","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110633","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110633"}}